1235 related articles for article (PubMed ID: 27540850)
1. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.
Nishino M; Giobbie-Hurder A; Hatabu H; Ramaiya NH; Hodi FS
JAMA Oncol; 2016 Dec; 2(12):1607-1616. PubMed ID: 27540850
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
[TBL] [Abstract][Full Text] [Related]
3. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
4. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
Sukari A; Nagasaka M; Alhasan R; Patel D; Wozniak A; Ramchandren R; Vaishampayan U; Weise A; Flaherty L; Jang H; Kim S; Gadgeel S
Anticancer Res; 2019 Feb; 39(2):781-790. PubMed ID: 30711957
[TBL] [Abstract][Full Text] [Related]
5. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
6. Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies.
Sui JD; Wang Y; Wan Y; Wu YZ
Drug Des Devel Ther; 2018; 12():1645-1657. PubMed ID: 29922039
[TBL] [Abstract][Full Text] [Related]
7. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
[TBL] [Abstract][Full Text] [Related]
8. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.
Nishino M; Ramaiya NH; Awad MM; Sholl LM; Maattala JA; Taibi M; Hatabu H; Ott PA; Armand PF; Hodi FS
Clin Cancer Res; 2016 Dec; 22(24):6051-6060. PubMed ID: 27535979
[TBL] [Abstract][Full Text] [Related]
9. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
10. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
[TBL] [Abstract][Full Text] [Related]
11. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis.
Wu J; Hong D; Zhang X; Lu X; Miao J
Sci Rep; 2017 Mar; 7():44173. PubMed ID: 28272463
[TBL] [Abstract][Full Text] [Related]
12. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.
O'Connor JM; Fessele KL; Steiner J; Seidl-Rathkopf K; Carson KR; Nussbaum NC; Yin ES; Adelson KB; Presley CJ; Chiang AC; Ross JS; Abernethy AP; Gross CP
JAMA Oncol; 2018 Aug; 4(8):e180798. PubMed ID: 29800974
[TBL] [Abstract][Full Text] [Related]
13. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
Suh CH; Park HS; Kim KW; Pyo J; Hatabu H; Nishino M
Lung Cancer; 2018 Sep; 123():60-69. PubMed ID: 30089596
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
15. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.
Voong KR; Hazell SZ; Fu W; Hu C; Lin CT; Ding K; Suresh K; Hayman J; Hales RK; Alfaifi S; Marrone KA; Levy B; Hann CL; Ettinger DS; Feliciano JL; Peterson V; Kelly RJ; Brahmer JR; Forde PM; Naidoo J
Clin Lung Cancer; 2019 Jul; 20(4):e470-e479. PubMed ID: 31031204
[TBL] [Abstract][Full Text] [Related]
16. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
17. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
Naidoo J; Wang X; Woo KM; Iyriboz T; Halpenny D; Cunningham J; Chaft JE; Segal NH; Callahan MK; Lesokhin AM; Rosenberg J; Voss MH; Rudin CM; Rizvi H; Hou X; Rodriguez K; Albano M; Gordon RA; Leduc C; Rekhtman N; Harris B; Menzies AM; Guminski AD; Carlino MS; Kong BY; Wolchok JD; Postow MA; Long GV; Hellmann MD
J Clin Oncol; 2017 Mar; 35(7):709-717. PubMed ID: 27646942
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Luo W; Wang Z; Tian P; Li W
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
[No Abstract] [Full Text] [Related]
[Next] [New Search]